Kimryn Rathmell: Researchers uncover new role of mutant RAS proteins in some of the deadliest cancers
Kimryn Rathmell shared on X:
“Exciting new discovery led by the NCI uncovers a new role of mutant RAS in driving cancer growth – by helping release a nuclear protein (EZH2) into the cytoplasm, which then facilitates the breakdown of a tumor suppressor protein and tumor growth.”
Dr. Kimryn Rathmell serves as the director of the National Cancer Institute.
She is a distinguished leader and researcher in the field of kidney cancer. Specializing in the research and treatment of complex and hereditary kidney cancers. She has held leadership positions with organizations such as the American Society of Clinical Oncology and the American Society for Clinical Investigation, she has been elected to esteemed academies including the Association of American Physicians, the American Academy of Arts and Sciences, and the National Academy of Medicine.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023